Zimmer Biomet (ZBH) Competitors

Penumbra (NYSE:PEN) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Is PEN or ZBH more profitable?

Penumbra has a net margin of 11.54% compared to Zimmer Biomet's net margin of 10.51%. Zimmer Biomet's return on equity of 12.76% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	11.54%	11.55%	8.76%
Zimmer Biomet	10.51%	12.76%	7.21%

Which has more volatility & risk, PEN or ZBH?

Penumbra has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of PEN or ZBH?

88.9% of Penumbra shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 5.0% of Penumbra shares are owned by company insiders. Comparatively, 0.7% of Zimmer Biomet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has higher earnings & valuation, PEN or ZBH?

Zimmer Biomet has higher revenue and earnings than Penumbra. Zimmer Biomet is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.19B	8.36	$14.01M	$3.76	68.10
Zimmer Biomet	$7.68B	2.60	$903.70M	$4.11	24.53

Do analysts rate PEN or ZBH?

Penumbra currently has a consensus price target of $302.93, suggesting a potential upside of 18.31%. Zimmer Biomet has a consensus price target of $112.44, suggesting a potential upside of 11.54%. Given Penumbra's stronger consensus rating and higher possible upside, research analysts clearly believe Penumbra is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.83
Zimmer Biomet	2 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.48

Does the media favor PEN or ZBH?

In the previous week, Penumbra had 12 more articles in the media than Zimmer Biomet. MarketBeat recorded 19 mentions for Penumbra and 7 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.16 beat Penumbra's score of 0.81 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	11 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Penumbra beats Zimmer Biomet on 9 of the 16 factors compared between the two stocks.